Cargando…
Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness
BACKGROUND: African‐American (AA) men tend to present with more aggressive prostate cancer (Gleason score >7) than European‐American (EA) men. Vitamin D and its metabolites are implicated in prostate cancer biology with vitamin D deficiency, indicated by its metabolite levels in serum or plasma,...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593756/ https://www.ncbi.nlm.nih.gov/pubmed/31077420 http://dx.doi.org/10.1002/pros.23824 |
_version_ | 1783430117178998784 |
---|---|
author | Ramakrishnan, Swathi Steck, Susan E. Arab, Lenore Zhang, Hongmei Bensen, Jeannette T. Fontham, Elizabeth T. H. Johnson, Candace S. Mohler, James L. Smith, Gary J. Su, L. Joseph Woloszynska, Anna |
author_facet | Ramakrishnan, Swathi Steck, Susan E. Arab, Lenore Zhang, Hongmei Bensen, Jeannette T. Fontham, Elizabeth T. H. Johnson, Candace S. Mohler, James L. Smith, Gary J. Su, L. Joseph Woloszynska, Anna |
author_sort | Ramakrishnan, Swathi |
collection | PubMed |
description | BACKGROUND: African‐American (AA) men tend to present with more aggressive prostate cancer (Gleason score >7) than European‐American (EA) men. Vitamin D and its metabolites are implicated in prostate cancer biology with vitamin D deficiency, indicated by its metabolite levels in serum or plasma, usually observed in AA men. OBJECTIVE: To determine if 1, 25‐dihydroxy vitamin D3 [1,25(OH)(2)D] plasma levels in AA and EA prostate cancer patients alter the risk of having aggressive prostate cancer. DESIGN: Research subjects from the North Carolina‐Louisiana Prostate Cancer Project (AA n = 435 and EA n = 532) were included. Plasma metabolites 1,25(OH)(2)D and 25‐hydroxyvitamin D3 [25(OH)D] were measured using liquid chromatography with tandem mass spectrophotometry. Research subjects were classified into low (Gleason sum < 7, stage T1‐T2, and Prostate‐specific antigen (PSA) < 9 ng/mL) or high (Gleason sum > 8 or Gleason sum = 7 with 4 + 3, or PSA > 20 ng/mL, or Gleason sum = 7 and stage T3‐T4) aggressive disease. RESULTS: Research subjects in the second and third tertiles of plasma levels of 1, 25(OH)(2)D had lower odds of high aggressive prostate cancer (AA [OR(T2vsT1): 0.66, 95%CI: 0.39‐1.12; OR(T3vsT1): 0.83, 95%CI: 0.49‐1.41] and EA [OR(T2vsT1): 0.68, 95%CI: 0.41‐1.11; OR(T3vsT1): 0.67, 95%CI: 0.40‐1.11]) compared with the first tertile, though confidence intervals included the null. Greater 1,25(OH)(2)D/25(OH)D molar ratios were associated with lower odds of high aggressive prostate cancer more evidently in AA (OR(Q4vsQ1): 0.45, CI: 0.24‐0.82) than in EA (OR(Q4vsQ1): 0.64, CI: 0.35‐1.17) research subjects. CONCLUSIONS: The 1,25(OH)(2)D/25(OH)D molar ratio was associated with decreased risk of high aggressive prostate cancer in AA men, and possibly in EA men. Further studies analyzing vitamin D polymorphisms, vitamin D binding protein levels, and prostatic levels of these metabolites may be useful. These studies may provide a better understanding of the vitamin D pathway and its biological role underlying health disparities in prostate cancer. |
format | Online Article Text |
id | pubmed-6593756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65937562019-07-10 Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness Ramakrishnan, Swathi Steck, Susan E. Arab, Lenore Zhang, Hongmei Bensen, Jeannette T. Fontham, Elizabeth T. H. Johnson, Candace S. Mohler, James L. Smith, Gary J. Su, L. Joseph Woloszynska, Anna Prostate Original Articles BACKGROUND: African‐American (AA) men tend to present with more aggressive prostate cancer (Gleason score >7) than European‐American (EA) men. Vitamin D and its metabolites are implicated in prostate cancer biology with vitamin D deficiency, indicated by its metabolite levels in serum or plasma, usually observed in AA men. OBJECTIVE: To determine if 1, 25‐dihydroxy vitamin D3 [1,25(OH)(2)D] plasma levels in AA and EA prostate cancer patients alter the risk of having aggressive prostate cancer. DESIGN: Research subjects from the North Carolina‐Louisiana Prostate Cancer Project (AA n = 435 and EA n = 532) were included. Plasma metabolites 1,25(OH)(2)D and 25‐hydroxyvitamin D3 [25(OH)D] were measured using liquid chromatography with tandem mass spectrophotometry. Research subjects were classified into low (Gleason sum < 7, stage T1‐T2, and Prostate‐specific antigen (PSA) < 9 ng/mL) or high (Gleason sum > 8 or Gleason sum = 7 with 4 + 3, or PSA > 20 ng/mL, or Gleason sum = 7 and stage T3‐T4) aggressive disease. RESULTS: Research subjects in the second and third tertiles of plasma levels of 1, 25(OH)(2)D had lower odds of high aggressive prostate cancer (AA [OR(T2vsT1): 0.66, 95%CI: 0.39‐1.12; OR(T3vsT1): 0.83, 95%CI: 0.49‐1.41] and EA [OR(T2vsT1): 0.68, 95%CI: 0.41‐1.11; OR(T3vsT1): 0.67, 95%CI: 0.40‐1.11]) compared with the first tertile, though confidence intervals included the null. Greater 1,25(OH)(2)D/25(OH)D molar ratios were associated with lower odds of high aggressive prostate cancer more evidently in AA (OR(Q4vsQ1): 0.45, CI: 0.24‐0.82) than in EA (OR(Q4vsQ1): 0.64, CI: 0.35‐1.17) research subjects. CONCLUSIONS: The 1,25(OH)(2)D/25(OH)D molar ratio was associated with decreased risk of high aggressive prostate cancer in AA men, and possibly in EA men. Further studies analyzing vitamin D polymorphisms, vitamin D binding protein levels, and prostatic levels of these metabolites may be useful. These studies may provide a better understanding of the vitamin D pathway and its biological role underlying health disparities in prostate cancer. John Wiley and Sons Inc. 2019-05-11 2019-07-01 /pmc/articles/PMC6593756/ /pubmed/31077420 http://dx.doi.org/10.1002/pros.23824 Text en © 2019 The Authors. The Prostate Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ramakrishnan, Swathi Steck, Susan E. Arab, Lenore Zhang, Hongmei Bensen, Jeannette T. Fontham, Elizabeth T. H. Johnson, Candace S. Mohler, James L. Smith, Gary J. Su, L. Joseph Woloszynska, Anna Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness |
title | Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness |
title_full | Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness |
title_fullStr | Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness |
title_full_unstemmed | Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness |
title_short | Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness |
title_sort | association among plasma 1,25(oh)(2)d, ratio of 1,25(oh)(2)d to 25(oh)d, and prostate cancer aggressiveness |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593756/ https://www.ncbi.nlm.nih.gov/pubmed/31077420 http://dx.doi.org/10.1002/pros.23824 |
work_keys_str_mv | AT ramakrishnanswathi associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT stecksusane associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT arablenore associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT zhanghongmei associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT bensenjeannettet associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT fonthamelizabethth associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT johnsoncandaces associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT mohlerjamesl associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT smithgaryj associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT suljoseph associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness AT woloszynskaanna associationamongplasma125oh2dratioof125oh2dto25ohdandprostatecanceraggressiveness |